CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLABOO3

Vitamin D Testing Laboratory Reimbursement

Defines Blue Cross Blue Shield Oklahoma reimbursement criteria and coding guidance for serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing, including clinical indications that support reimbursement, monitoring frequency limits, and tests that are not reimbursable.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyVitamin D Testing Laboratory Reimbursement

Policy CodePolicy CPCPLABOO3

Change TypeRevised (03/15/2024)

Effective DateMar 15, 2024

Next Review Date

Key ActionProviders must submit accurate documentation supporting that testing falls within listed indications to support reimbursement; BCBSOK may request additional documentation.

POLICY UPDATE CHANGES

03/15/2024 - Document updated with literature review; reimbursement information unchanged; references revised.

06/01/2023 - Document updated with literature review; reimbursement information revised for clarity; references revised.

11/01/2022 - New policy created.

2Primary tests addressed (25-OH D, 1,25-(OH)2 D)

>=12 wksMinimum recheck interval after supplementation

2Max tests/year until goal achieved

Policy summary

This policy defines Blue Cross Blue Shield of Oklahoma (BCBSOK) reimbursement criteria for laboratory measurement of vitamin D, specifically 25-hydroxyvitamin D (total) and 1,25-dihydroxyvitamin D serum testing, and provides coding guidance and limits on monitoring frequency.

The purpose is to describe clinical indications that support reimbursement (including disease-specific indications and disorders of vitamin D metabolism), to identify tests that are not reimbursable (routine screening and use of 1,25-dihydroxyvitamin D as a screening test), and to note that not all requirements apply to every product — plan documents govern coverage for members.

High-level monitoring limits include a minimum recheck interval of >= 12 weeks after initiation of supplementation for documented deficiency, an operational limit of <= 2 tests per year for monitoring until the therapeutic goal is achieved, and annual testing thereafter once therapeutic range is reached.

Policy metadata and thresholds

policy_numberCPCPLABOO3

effective_date2024-03-15

last_review2024-03-15

next_review

statusCURRENT

scope_summaryDefines Blue Cross Blue Shield Oklahoma reimbursement criteria and coding guidance for serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing, including clinical indications that support reimbursement, monitoring frequency limits, and tests that are not reimbursable.

Monitoring interval after supplementation initiation>= 12 weeks

Maximum repeat tests per year until therapeutic goal achieved<= 2 tests per year

Post-therapeutic monitoring frequencyannual testing

Reimbursable and non-reimbursable testing criteria

Reimbursable 25-hydroxyvitamin D testing

25-hydroxyvitamin D (total) serum testing may be reimbursable when any of the following clinical situations apply:

ANY of the following

Individual has an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density (see Note 1).
Individual is suspected of hypervitaminosis of Vitamin D.

Reimbursable D2 and D3 fraction testing

As part of total 25-hydroxyvitamin D analysis:

Testing for D2 and D3 fractions of 25-hydroxyvitamin D may be reimbursable as part of the total analysis.

Repeat testing for documented deficiency (monitoring)

Repeat 25-hydroxyvitamin D testing may be reimbursable for documented deficiency under these conditions:

ALL of the following

Repeat testing performed at least 12 weeks after initiation of vitamin D supplementation.>=12 weeks
Frequency limits
- Repeat testing for monitoring of supplementation therapy should not exceed 2 testing instances per year until therapeutic goal is achieved.<=2 tests/year
  Operational limit: ≤2 tests/year until goal achieved.
- Once therapeutic range has been reached, annual testing may be reimbursable.annual
  Operational limit: annual testing thereafter.

Reimbursable 1,25-dihydroxyvitamin D testing

1,25-dihydroxyvitamin D serum testing may be reimbursable for evaluation/treatment of conditions associated with defects in vitamin D metabolism (see Note 2).

Test is ordered for evaluation or treatment of conditions listed in Note 2 (disorders of calcium metabolism, familial hypophosphatemia, Fanconi syndrome, hyperparathyroidism/hypoparathyroidism, individuals receiving hyperalimentation, neonatal hypocalcemia, osteogenesis imperfecta, osteomalacia, osteopetrosis, renal/urinary calculus, tuberculosis, rickets, sarcoidosis, Stage III-V CKD and ESRD).

Not reimbursable vitamin D testing

The following testing is not reimbursable:

ANY of the following

Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals and/or during general encounters.
Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency.

Procedure and coding guidance

Procedure Codes (listed as not all-encompassing)mixed

No codes listed

Providers must submit claims using valid HIPAA-approved procedure, diagnosis, and drug codes and follow standard coding guidelines; inclusion of a code in the policy does not guarantee coverage.

Accurate clinical documentation demonstrating that testing falls within the listed indications (Note 1 for 25-OH D, Note 2 for 1,25-(OH)2 D) should be submitted and BCBSOK may request additional documentation.

Claims are subject to code edit protocols and review against plan/contract terms and may be denied if they do not meet the policy criteria.

What providers must do

Documentation Required

Document clinical indication

Providers must submit accurate documentation supporting that testing falls within listed indications (Note 1 for 25-OH D, Note 2 for 1,25-(OH)2 D) to support reimbursement; BCBSOK may request additional documentation.

Billing Rule

Use appropriate HIPAA-approved codes

Providers are expected to submit claims using valid HIPAA-approved procedure, diagnosis and drug codes and to follow standard coding guidelines; inclusion of a code in the policy does not guarantee coverage.

Denial Risk

Claims subject to review and denial if not meeting criteria

Claims for routine screening or for 1,25-dihydroxyvitamin D used as a screen may be denied as not reimbursable; claims are subject to code edit protocols and plan/contract terms.

Evidence and guideline basis

The policy is based on a literature review and multiple cited clinical guidelines and studies; a references list is provided in the document to support the policy statements.

References include clinical practice guidelines, systematic reviews, and primary studies relevant to vitamin D testing, management, and assay considerations.

The provided references are used to support the specified clinical indications and monitoring limits in the reimbursement criteria.

OpenPayer